Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis |
| March 20, 2018 | March 2018 Bond Updates |
|
BOSTON, March 20, 2018 /PRNewswire-USNewswire/ -- The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their... |
| View more at: https://www.prnewswire.com/news-releases/harvard-bioengineers-biomaterial-based-cancer-immunotherapies-to-be-developed-by-novartis-300615921.html |
| Related News |
|